Adicet Bio Inc
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company's lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy express… Read more
Adicet Bio Inc (ACET) - Total Assets
Latest total assets as of December 2025: $192.35 Million USD
Based on the latest financial reports, Adicet Bio Inc (ACET) holds total assets worth $192.35 Million USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Adicet Bio Inc - Total Assets Trend (2008–2025)
This chart illustrates how Adicet Bio Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Adicet Bio Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Adicet Bio Inc's total assets of $192.35 Million consist of 83.7% current assets and 16.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 20.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2008–2025)
This chart illustrates how Adicet Bio Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Adicet Bio Inc's current assets represent 83.7% of total assets in 2025, a decrease from 94.3% in 2008.
- Cash Position: Cash and equivalents constituted 20.2% of total assets in 2025, down from 22.6% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 2.0% in 2008.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Adicet Bio Inc Competitors by Total Assets
Key competitors of Adicet Bio Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Adicet Bio Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Adicet Bio Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Adicet Bio Inc is currently not profitable relative to its asset base.
Adicet Bio Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.47 | 9.29 | 9.10 |
| Quick Ratio | 7.47 | 9.29 | 8.99 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $139.40 Million | $ 160.74 Million | $ 203.92 Million |
Adicet Bio Inc - Advanced Valuation Insights
This section examines the relationship between Adicet Bio Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.64 |
| Latest Market Cap to Assets Ratio | 0.25 |
| Asset Growth Rate (YoY) | -12.7% |
| Total Assets | $192.35 Million |
| Market Capitalization | $47.35 Million USD |
Valuation Analysis
Below Book Valuation: The market values Adicet Bio Inc's assets below their book value (0.25 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Adicet Bio Inc's assets decreased by 12.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Adicet Bio Inc (2008–2025)
The table below shows the annual total assets of Adicet Bio Inc from 2008 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $192.35 Million | -12.65% |
| 2024-12-31 | $220.22 Million | +6.23% |
| 2023-12-31 | $207.29 Million | -37.31% |
| 2022-12-31 | $330.69 Million | -2.43% |
| 2021-12-31 | $338.94 Million | +120.33% |
| 2020-12-31 | $153.84 Million | +88.55% |
| 2019-12-31 | $81.59 Million | -25.79% |
| 2018-12-31 | $109.94 Million | +99.19% |
| 2017-12-31 | $55.19 Million | -89.79% |
| 2016-12-31 | $540.78 Million | +10.41% |
| 2015-12-31 | $489.77 Million | +4.66% |
| 2014-12-31 | $467.98 Million | +44.69% |
| 2013-12-31 | $323.43 Million | +8.07% |
| 2012-12-31 | $299.28 Million | +1.45% |
| 2011-12-31 | $294.99 Million | +36.22% |
| 2010-12-31 | $216.56 Million | +14.41% |
| 2009-12-31 | $189.27 Million | -7.90% |
| 2008-12-31 | $205.50 Million | -- |